SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biologics

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2134295

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2134295

GLP-1 Agonists Weight Loss Drugs Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 312 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

The global GLP-1 agonists weight loss drugs market is experiencing exceptional growth as highly effective incretin-based therapies transform the medical management of obesity. Strong clinical outcomes, rising global obesity prevalence, and expanding recognition of obesity as a chronic disease are driving unprecedented patient demand and major manufacturing investments across the pharmaceutical industry. The global GLP-1 agonists weight loss drugs market is expected to be valued at US$ 38.00 Billion in 2026 and is projected to reach US$ 147.62 Billion by 2033, growing at a CAGR of 21.4% between 2026 and 2033.

Market Insights:

GLP-1 receptor agonists mimic a natural gut hormone that regulates appetite, slows gastric emptying, and improves insulin response, leading to significant and sustained weight reduction. Newer dual and triple agonists that also target GIP and glucagon receptors are demonstrating even greater weight loss in clinical trials. The market is shifting from weekly injectables toward oral formulations and longer-acting options that could improve convenience and adherence. Evidence of cardiovascular, kidney, and metabolic benefits is broadening the therapeutic value of these drugs. Supply constraints, pricing pressures, and reimbursement debates remain key issues as manufacturers scale up production capacity worldwide.

Drivers:

The main driver of the market is the growing global burden of obesity and overweight conditions, which affect a large share of adults and a rising number of children. Clinical trial results showing substantial weight loss and cardiovascular risk reduction are encouraging physicians to prescribe these therapies more widely. Expanding regulatory approvals for additional indications, such as sleep apnea and cardiovascular protection, are increasing eligible patient populations. Greater public awareness, driven by media attention and digital health platforms, is boosting patient demand. Moreover, improving insurance coverage and employer health programs are gradually widening access, while telehealth services are simplifying diagnosis and prescribing.

Business Opportunity:

Significant opportunities exist for companies developing oral small-molecule GLP-1 agonists, which could lower manufacturing costs and expand access beyond injectable therapies. Next-generation multi-agonist drugs with higher efficacy and improved tolerability represent a major pipeline opportunity. Patent expiries for early molecules are opening the door for biosimilar and generic versions in several markets, supporting affordability in emerging economies. Combination therapies that preserve lean muscle mass during weight loss are attracting growing research interest. Additionally, integrated care models combining medication with digital coaching, nutrition support, and remote monitoring can improve outcomes and create new service-based revenue streams.

Region Analysis:

North America dominates the global GLP-1 agonists weight loss drugs market, supported by high obesity prevalence, strong physician adoption, premium drug pricing, and broad availability through retail and online pharmacies in the United States. Europe holds a significant share as regulatory approvals expand and national health systems evaluate reimbursement for obesity treatment. Asia Pacific is expected to be the fastest-growing region, driven by rising obesity rates, growing healthcare spending, local manufacturing, and upcoming lower-cost versions in China, India, and Japan. Latin America is showing increasing uptake in Brazil and Mexico, where obesity rates are high, while the Middle East & Africa is expanding rapidly in Gulf countries.

Key Players:

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Pfizer Inc.
  • AstraZeneca plc
  • Amgen Inc.
  • Roche Holding AG
  • Viking Therapeutics, Inc.
  • Zealand Pharma A/S
  • Boehringer Ingelheim International GmbH
  • Structure Therapeutics Inc.

Segmentation:

By Drug Class

  • Semaglutide-Based
  • Tirzepatide-Based
  • Others

By Route of Administration

  • Injectable
  • Oral

By Indication

  • Obesity/Chronic Weight Management
  • Type 2 Diabetes with Weight Management

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global GLP-1 Agonists Weight Loss Drugs Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global GLP-1 Agonists Weight Loss Drugs Market Outlook, 2020-2033

  • 3.1. Global GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 3.1.1. Semaglutide-Based
    • 3.1.2. Tirzepatide-Based
    • 3.1.3. Others
  • 3.2. Global GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 3.2.1. Injectable
    • 3.2.2. Oral
  • 3.3. Global GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 3.3.1. Obesity/Chronic Weight Management
    • 3.3.2. Type 2 Diabetes with Weight Management
  • 3.4. Global GLP-1 Agonists Weight Loss Drugs Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America GLP-1 Agonists Weight Loss Drugs Market Outlook, 2020-2033

  • 4.1. North America GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 4.1.1. Semaglutide-Based
    • 4.1.2. Tirzepatide-Based
    • 4.1.3. Others
  • 4.2. North America GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 4.2.1. Injectable
    • 4.2.2. Oral
  • 4.3. North America GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 4.3.1. Obesity/Chronic Weight Management
    • 4.3.2. Type 2 Diabetes with Weight Management
  • 4.4. North America GLP-1 Agonists Weight Loss Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 4.4.2. U.S. GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 4.4.3. U.S. GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 4.4.4. Canada GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 4.4.5. Canada GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 4.4.6. Canada GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, 2020-2033

  • 5.1. Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 5.1.1. Semaglutide-Based
    • 5.1.2. Tirzepatide-Based
    • 5.1.3. Others
  • 5.2. Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 5.2.1. Injectable
    • 5.2.2. Oral
  • 5.3. Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 5.3.1. Obesity/Chronic Weight Management
    • 5.3.2. Type 2 Diabetes with Weight Management
  • 5.4. Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 5.4.2. Germany GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.3. Germany GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 5.4.4. Italy GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 5.4.5. Italy GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.6. Italy GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 5.4.7. France GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 5.4.8. France GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.9. France GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 5.4.10. U.K. GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 5.4.11. U.K. GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.12. U.K. GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 5.4.13. Spain GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 5.4.14. Spain GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.15. Spain GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 5.4.16. Russia GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 5.4.17. Russia GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.18. Russia GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 5.4.19. Rest of Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 5.4.20. Rest of Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.21. Rest of Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Outlook, 2020-2033

  • 6.1. Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 6.1.1. Semaglutide-Based
    • 6.1.2. Tirzepatide-Based
    • 6.1.3. Others
  • 6.2. Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 6.2.1. Injectable
    • 6.2.2. Oral
  • 6.3. Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 6.3.1. Obesity/Chronic Weight Management
    • 6.3.2. Type 2 Diabetes with Weight Management
  • 6.4. Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 6.4.2. China GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.3. China GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 6.4.4. Japan GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 6.4.5. Japan GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.6. Japan GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 6.4.7. South Korea GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 6.4.8. South Korea GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.9. South Korea GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 6.4.10. India GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 6.4.11. India GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.12. India GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 6.4.13. Southeast Asia GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 6.4.14. Southeast Asia GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.15. Southeast Asia GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 6.4.16. Rest of SAO GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 6.4.17. Rest of SAO GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.18. Rest of SAO GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America GLP-1 Agonists Weight Loss Drugs Market Outlook, 2020-2033

  • 7.1. Latin America GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 7.1.1. Semaglutide-Based
    • 7.1.2. Tirzepatide-Based
    • 7.1.3. Others
  • 7.2. Latin America GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 7.2.1. Injectable
    • 7.2.2. Oral
  • 7.3. Latin America GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 7.3.1. Obesity/Chronic Weight Management
    • 7.3.2. Type 2 Diabetes with Weight Management
  • 7.4. Latin America GLP-1 Agonists Weight Loss Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 7.4.2. Brazil GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 7.4.3. Brazil GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 7.4.4. Mexico GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 7.4.5. Mexico GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 7.4.6. Mexico GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 7.4.7. Argentina GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 7.4.8. Argentina GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 7.4.9. Argentina GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 7.4.10. Rest of LATAM GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 7.4.11. Rest of LATAM GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 7.4.12. Rest of LATAM GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa GLP-1 Agonists Weight Loss Drugs Market Outlook, 2020-2033

  • 8.1. Middle East & Africa GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 8.1.1. Semaglutide-Based
    • 8.1.2. Tirzepatide-Based
    • 8.1.3. Others
  • 8.2. Middle East & Africa GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 8.2.1. Injectable
    • 8.2.2. Oral
  • 8.3. Middle East & Africa GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 8.3.1. Obesity/Chronic Weight Management
    • 8.3.2. Type 2 Diabetes with Weight Management
  • 8.4. Middle East & Africa GLP-1 Agonists Weight Loss Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 8.4.2. GCC GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.3. GCC GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 8.4.4. South Africa GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 8.4.5. South Africa GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.6. South Africa GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 8.4.7. Egypt GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 8.4.8. Egypt GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.9. Egypt GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 8.4.10. Nigeria GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 8.4.11. Nigeria GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.12. Nigeria GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
    • 8.4.13. Rest of Middle East GLP-1 Agonists Weight Loss Drugs Market Outlook, by Drug Class, 2020-2033
    • 8.4.14. Rest of Middle East GLP-1 Agonists Weight Loss Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.15. Rest of Middle East GLP-1 Agonists Weight Loss Drugs Market Outlook, by Indication, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Novo Nordisk A/S
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Eli Lilly and Company
    • 9.4.3. Pfizer Inc.
    • 9.4.4. AstraZeneca plc
    • 9.4.5. Amgen Inc.
    • 9.4.6. Roche Holding AG
    • 9.4.7. Viking Therapeutics, Inc.
    • 9.4.8. Zealand Pharma A/S
    • 9.4.9. Boehringer Ingelheim International GmbH
    • 9.4.10. Structure Therapeutics Inc.

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!